Phaeohyphomycosis refers to infections caused by darkly pigmented fungi. These fungi rarely cause lifethreatening disease. We reviewed 101 cases of culture-proven primary central nervous system phaeohyphomycosis reported in the English-language literature from 1966 to 2002. The most frequently isolated species was Cladophialophora bantiana. The next most frequent isolate was Ramichloridium mackenziei, seen exclusively in patients from the Middle East. More than one-half of the cases occurred in patients with no known underlying immunodeficiency. Mortality rates were high regardless of immune status. Therapy is not standardized, although the combination of amphotericin B, flucytosine, and itraconazole may improve survival rates. Newer azoles, such as voriconazole, also have a broad spectrum of activity against these fungi, although clinical experience is limited. Complete excision of brain lesions may provide better results than simple aspiration. An aggressive medical and surgical approach is warranted in treating these infections to optimize outcomes.
4 (4%) of 101 patients had neutropenia, most often related to recent chemotherapy. Three patients had undergone bone marrow transplantation, and 15 (15%) had received a solid organ transplant. Only 1 patient was HIV positive with AIDS. Six patients (6%) used injection drugs.
Clinical characteristics. The most common clinical findings are listed in table 2. All patients had у1 finding, and 75 (81%) of 93 patients for whom such data were reported had у2 findings at presentation. Brain abscess was the most common presentation, seen in 87 cases (87%). Single lesions were present in 62 (71%) of those cases. In all cases for which histopathologic findings were reported (75 of 87 cases, 86%), the presence of hyphae was noted, although granulomatous inflammation was noted in only 36 (48%) of 75 cases. In addition, there were 9 cases of meningitis (9% of reported cases), 2 cases of encephalitis (2%), 2 cases of myelitis (2%), and 1 case of arachnoiditis (1%). The results of tests of CSF samples obtained from 31 case patients are shown in table 3. Only 3 patients with cases of brain abscess had normal CSF findings. Significant CSF eosinophilia was noted in 2 patients. Opening pressure was not recorded in most cases, but ranged from normal (i.e., Therapy. The majority of patients were treated with a combination of medical and surgical therapy. Thirteen patients received no therapy, and 18 patients received only surgical therapy. Of those receiving surgery for brain abscess, 37 patients had complete excisions, 6 had partial excisions, and 16 had simple (often multiple) aspirations. The most frequently used drug was amphotericin B, which was used in 59 (88%) of the 67 cases in which antifungal therapy was administered. Lipid formulations of amphotericin B were used in only 8 patients, 5 of whom survived. Flucytosine (5-FC) was the next most commonly used drug, often used in combination with amphotericin B (in 24 cases). Itraconazole was the most azole most commonly used, usually in combination with amphotericin B (in 18 cases). Ketoconazole, miconazole, and fluconazole were used infrequently. Newer azoles, such as voriconazole, posaconazole, and ravuconazole, were not used in any patient. Combination therapy was used in 39 patients.
Outcomes. Overall mortality was 73% (66 of 91 patients for whom outcome was reported). Among patients with preexisting immunodeficiency, the mortality was 71% (24 of 34), equivalent to that seen among immunocompetent patients, among whom the mortality was 74% (42 of 57). In solid organ transplantation recipients, mortality was 64% (9 of 14). All 13 patients who received no therapy died. Treatment with the combination of amphotericin B, 5-FC, and itraconazole was associated with improved survival, compared with other medical regimens, with 17% mortality (1 of 6 patients) versus 74% mortality (32 of 43 patients), respectively ( ) ( figure 2 an association with improved survival. Of patients who received only surgical therapy, 77% (10 of 13) died. For the remaining patients, surgery was not, in general, associated with improved outcomes. However, of those patients who underwent therapeutic surgery (as opposed to diagnostic aspiration), complete excision of brain abscesses was associated with improved survival (mortality, 62% [23 of 37 patients]), compared with aspiration or partial excision (mortality, 86% [19 of 22] ; P p ). There was no difference in mortality between patients .02 with brain abscess versus those with other CNS infections. There were no instances of documented survival among patients with infection due to R. mackenziei. Some patients who were considered to have responded to therapy did not have prolonged follow-up. On the basis of cases in which recurrences occurred several months after initial therapy, we considered patients who were free of symptoms for 1 year to be cured. When this definition of cure was used, only 10 patients had documented cure. Although lipid amphotericin B preparations and itraconazole were used more frequently in recent years, overall mortality was not significantly changed, compared with mortality during earlier time periods.
DISCUSSION
Life-threatening fungal infections, particularly due to molds, are often associated with severe immunocompromise. Primary phaeohyphomycosis of the CNS appears to be a frequent exception to this rule. In this series of 101 patients, more than one-half had no underlying immunodeficiency or risk factor for fungal infection. In addition, the clinical management of patients with primary CNS phaeohyphomycosis is problematic as a result of its poor response to standard antifungal therapies. Because these are uncommon infections, combining data from individual case reports is a reasonable approach to attempt to determine optimal treatment strategies. However, one of the difficulties associated with retrospective case reviews is the inconsistent nature of individual case reports with regard to the clinical details and follow-up of each case. This results in data that is less than ideal for making conclusive statements about therapy and, in particular, about outcomes. The statements made in this review, as well as statistical data on outcomes, should be interpreted in light of these considerations.
The common feature among agents of phaeohyphomycosis is the presence of melanin in their cell walls, which imparts the characteristic dark color to their conidia and hyphae. It may also play an important role in the pathogenesis of infections caused by these fungi. Melanin is a known virulence factor in other fungi and has been extensively studied in Cryptococcus neoformans and Wangiella dermatitidis [92] [93] [94] [95] . Laboratory-derived strains of these fungi that lack melanin demonstrate markedly reduced virulence in murine models of infection [96] . Several mechanisms have been proposed by means of which melanin may act as a virulence factor [97] [98] [99] . It is thought to confer a protective advantage by scavenging free radicals and hypochlorite that are produced by phagocytic cells in their oxidative burst and that would normally kill most organisms [95] . In addition, melanin may bind to hydrolytic enzymes, thereby preventing their action on the plasma membrane. These multiple functions may help explain the pathogenic potential of some dematiaceous fungi, even in immunocompetent hosts. The pathogenesis of primary CNS phaeohyphomycosis is unknown at present. Except for one case, the patients in this case series did not have sinusitis or otitis media as part of their infection, and local extension of an infectious focus therefore seems unlikely (the patient with sinusitis had a brain abscess on the side opposite the sinusitis [14] ). This leaves the hematogenous route as a more likely source of the CNS infection, presumably from an initial subclinical pulmonary focus (because inhalation is the probable means of exposure for these environmental fungi). In addition, 5 patients had injection drug use as their only risk factor, including 3 patients infected with Chaetomium species. It remains unclear why these fungi cause CNS disease preferentially. An intriguing possibility is that melanin itself may be responsible for the CNS localization. Among malignancies, malignant melanoma has one of the highest rates of CNS metastasis (as much as 90% in some autopsy series) [100] . Receptors that recognize melanin or its biochemical by- products could allow these fungi to cross the blood-brain barrier and enter the brain parenchyma. However, human melanin (derived from tyrosine) and fungal melanin (mostly derived from acetate) are different biochemically, although they share the same physicochemical properties. This notion is speculative and does not explain why so few individuals are infected when, presumably, many more individuals are exposed. Subtle immunodeficiency that predisposes individuals to these infections may play a role as well. Guidelines are available regarding the proper handling of potentially infectious fungi in the laboratory setting [101] . It is suggested that certain well-known fungi, such as Coccidioides immitis and Histoplasma capsulatum, only be handled within a Biosafety Level 3 facility, which requires a separate negativepressure room [101] . Recently, agents of phaeohyphomycosis, in particular C. bantiana, have been included in the list of fungi that should be kept under Biosafety Level 2 containment [101] . This seems reasonable given their propensity, albeit rarely, for causing life-threatening infection in normal individuals.
The diagnosis of phaeohyphomycosis can be difficult because dematiaceous fungi are commonly soil inhabitants and are often considered contaminants when identified in culture. As with other filamentous fungi, identification in culture requires expert interpretation of colony and microscopic morphology. No molecular techniques are presently available to rapidly and reliably identify these fungi to even the genus level. In tissue, however, they usually have a characteristic appearance of irregularly swollen hyphae with yeastlike structures, in contrast to Aspergillus species, which typically show septate, acutely branching, straight-walled hyphae. The melanin-specific Masson-Fontana stain has been used to confirm the presence of dematiaceous hyphae in tissue [6] . However, Kimura and McGinnis [102] reported that other fungi, such as Aspergillus fumigatus and members of the Zygomycetes, may also stain positive, although less consistently. Culture and microscopic examination remain the definitive methods to identify dematiaceous fungi.
Clinical presentations varied considerably, although у1 neurologic sign or symptom was present in all cases where they were noted. However, the classic triad of fever, headache, and focal neurologic deficits described in patients with brain abscess was rarely observed. Single lesions were present in the majority of cases of brain abscess. The results of an examination of CSF samples were usually abnormal, but hypoglycorrhachia was uncommon. It should be noted that performing lumbar puncture for patients with cerebral mass lesions is not recommended, at least not without the availability of prompt neurosurgical assistance, if needed [103] [104] [105] .
Most agents of phaeohyphomycosis are found in soil throughout the world, as reflected in the distribution of cases. Given how ubiquitous these fungi are in the environment, it is likely that most, if not all, individuals are exposed to them. Many of the cases in immunocompetent individuals occur in rural settings, possibly as a result of more prevalent soil exposure. However, it is interesting to note that infections due to R. mackenziei have only been seen in the Middle East region, and this may reflect a limited geographic range for this organism. In addition, isolates previously identified as Ramichloridium obovoideum are actually R. mackenziei [52, 106] . This species may be particularly virulent, because there have been no documented survivors to date.
C. bantiana has several older names in the literature, including Cladosporium trichoides, Cladosporium bantianum, and Xylohypha bantiana [107] . It was first described in a cultureproven case of cerebral phaeohyphomycosis by Binford et al. [13] in 1952. In this review, we found that C. bantiana is the most commonly isolated species, which likely reflects its worldwide distribution. However, its precise ecological niche is not known [7] . Unknown virulence factors specific to this organism may play a role in establishing infection. Infection with C. bantiana occurs more commonly in immunocompetent patients than in immunocompromised patients; infections in immunocompetent patients accounted for 35 (73%) of 48 cases of C. bantiana infection. The mortality rate was 70% (30 of 43 patients) among patients for whom outcome was reported. Almost all infections caused by this fungus have been confined to the CNS, indicating a highly neurotropic potential. Given the above considerations, it may be reasonable to consider this species a true pathogen, as opposed to an opportunist.
There is no standard therapy for these often fatal infections, and many regimens have been described in the literature. In this review, we found that the combination of amphotericin B, 5-FC, and itraconazole was associated with improved survival, although there were relatively few cases in which this triple combination was used. Some species of dematiaceous fungi are resistant in vitro to amphotericin B, which is often used as the gold standard for therapy [108] . The use of lipid preparations of amphotericin B has been suggested as a way to increase the dose of amphotericin B while reducing its toxic effects, particularly nephrotoxicity. However, these preparations were used infrequently in this series, and firm conclusions regarding their use are not possible. Lipid formulations certainly do allow the use of higher doses and longer courses of amphotericin B than is routinely possible with the standard deoxycholate formulation, which may improve efficacy. In a maximum-tolerateddose study of liposomal amphotericin B, dosages as high as 10 mg/kg per day were suggested for CNS fungal infections not responding to standard doses [109] . In addition, an animal study of Candida infection of the CNS showed that liposomal amphotericin B had significantly higher brain-tissue concentrations than did other amphotericin B preparations [110] .
Among available agents, itraconazole and voriconazole have the most consistent and potent activity, and intravenous formulations are available [108, 111] . Itraconazole penetrates poorly into the CSF, although it does achieve high levels in brain tissue [112] . In contrast, voriconazole achieves good penetration into the CSF and brain tissue [113] . It has been used to successfully treat CNS aspergillosis as well as cases of non-CNS phaeohyphomycosis [114, 115] . Although azoles were not independently associated with improved outcomes, they were used relatively infrequently among the cases reviewed and have the broadest overall activity against this group of fungi. Highdose regimens may provide better efficacy, but this has not been studied prospectively.
5-FC has activity against some dematiaceous fungi, in particular C. bantiana, and is one of the few antifungal agents with excellent penetration into the CSF, which may explain its in vivo activity [116, 117] . Its mechanism of action against agents of phaeohyphomycosis is thought to be similar to that against other fungi studied: inhibition of DNA and RNA synthesis [118] . The activity of 5-FC against dematiaceous fungi is supported by in vitro studies and animal models of systemic and cerebral phaeohyphomycosis [117, 119, 120] .
Other agents have also demonstrated activity against dematiaceous fungi. Terbinafine has been shown to have significant in vitro activity [121] . It is indicated primarily for dermatophyte infections and onychomycosis, although it has been used in treating other fungal infections [122] . There are no reports of its use in the treatment of cerebral phaeohyphomycosis, however. Some of the many new antifungal agents being developed hold promise for improving the therapy of these infections in the future. Posaconazole and ravuconazole are potent new azole derivatives with a generally broad spectrum of activity against dematiaceous fungi [123] [124] [125] [126] . Posaconazole has also demonstrated activity in a murine model of CNS phaeohyphomycosis caused by R. mackenziei [127] . Other compounds, such as echinocandins (e.g., caspofungin) and nikkomycins, which act on the fungal cell wall, do not appear to be as active in vitro as are the azoles, and their role in the treatment of phaeohyphomycosis is unclear at present [124] .
Further studies of antifungal combinations are needed to explore potentially useful regimens for treatment of these refractory infections.
CNS phaeohyphomycosis, primarily brain abscess, is an unusual and unique manifestation of infection caused by dematiaceous fungi, often occurring in patients without immunodeficiency. In patients presenting with this clinical scenario, biopsy and culture are essential, and unusual fungi should not be routinely considered contaminants. At present, initial combination therapy with (high-dose lipid) amphotericin B, 5-FC, and itraconazole (or voriconazole, on the basis of in vitro data) may be reasonable. Complete excision of brain abscesses may lead to better outcomes than simple aspiration or partial excision. An aggressive therapeutic approach is needed, given the high mortality rate associated with these infections.
